Zobrazeno 1 - 10 of 42 pro vyhledávání: '"Puttur J"'
1
Akademický článek
Design, synthesis and SAR of antitubercular benzylpiperazine ureas.
Autor: Satish S; Ambernath Organics Pvt. Ltd., 222, The Summit Business Bay, Andheri (E), Mumbai, 400 093, India., Chitral R; Ambernath Organics Pvt. Ltd., 222, The Summit Business Bay, Andheri (E), Mumbai, 400 093, India., Kori A; Ambernath Organics Pvt. Ltd., 222, The Summit Business Bay, Andheri (E), Mumbai, 400 093, India., Sharma B; Ambernath Organics Pvt. Ltd., 222, The Summit Business Bay, Andheri (E), Mumbai, 400 093, India., Puttur J; Ambernath Organics Pvt. Ltd., 222, The Summit Business Bay, Andheri (E), Mumbai, 400 093, India., Khan AA; Department of Pharmaceutical Chemistry, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai, 400 098, India., Desle D; Department of Pharmaceutical Chemistry, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai, 400 098, India., Raikuvar K; Department of Pharmaceutical Chemistry, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai, 400 098, India., Korkegian A; TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue E, Suite 400, Seattle, WA, 98102, USA., Martis EAF; Department of Pharmaceutical Chemistry, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai, 400 098, India., Iyer KR; Department of Pharmaceutical Chemistry, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai, 400 098, India., Coutinho EC; Department of Pharmaceutical Chemistry, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai, 400 098, India., Parish T; TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue E, Suite 400, Seattle, WA, 98102, USA., Nandan S; Ambernath Organics Pvt. Ltd., 222, The Summit Business Bay, Andheri (E), Mumbai, 400 093, India. santosh.nandan@gmail.com.
Publikováno v: Molecular diversity [Mol Divers] 2022 Feb; Vol. 26 (1), pp. 73-96. Date of Electronic Publication: 2021 Jan 01.
Zobrazit plný text záznamu
2
Akademický článek
4-Hydroxy-2-pyridone Derivatives and the δ-pyrone Isostere as Novel Agents Against Mycobacterium smegmatis Biofilm Inhibitors.
Autor: Borkar MR; Department of Pharmaceutical Chemistry, Bombay College of Pharmacy, Sunder Nagar, Kalina, Santacruz (E), Mumbai 400 098, India., Nandan S; Ambernath Organics, 307/314, Creative Industries Premises, Road No. 2, Sunder Nagar, Kalina, Santacruz (E), Mumbai 400 098, India., Nagaraj HKM; BioOrganics, B-64/1, III Stage, Industrial Area, Peenya, Bengaluru 560 058, India., Puttur J; Ambernath Organics, 307/314, Creative Industries Premises, Road No. 2, Sunder Nagar, Kalina, Santacruz (E), Mumbai 400 098, India., Manniyodath J; Molecular Biophysics Unit, Indian Institute of Science, Bengaluru 560 012, India., Chatterji D; Molecular Biophysics Unit, Indian Institute of Science, Bengaluru 560 012, India., Coutinho EC; Department of Pharmaceutical Chemistry, Bombay College of Pharmacy, Sunder Nagar, Kalina, Santacruz (E), Mumbai 400 098, India.
Publikováno v: Medicinal chemistry (Shariqah (United Arab Emirates)) [Med Chem] 2019; Vol. 15 (1), pp. 28-37.
Zobrazit plný text záznamu
3
Akademický článek
Left-Hand Side Exploration of Novel Bacterial Topoisomerase Inhibitors to Improve Selectivity against hERG Binding.
Autor: Hameed P S; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India., Manjrekar P; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India., Raichurkar A; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India., Shinde V; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India., Puttur J; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India., Shanbhag G; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India., Chinnapattu M; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India., Patil V; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India., Rudrapatana S; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India., Sharma S; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India., Kumar CN; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India., Nandishaiah R; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India., Madhavapeddi P; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India., Sriram D; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India., Solapure S; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India., Sambandamurthy VK; AstraZeneca India Pvt. Ltd , Avishkar, Bellary Road, Bangalore-560024, India.
Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2015 May 22; Vol. 6 (7), pp. 741-6. Date of Electronic Publication: 2015 May 22 (Print Publication: 2015).
Zobrazit plný text záznamu
4
Akademický článek
Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate.
Autor: Hameed P S; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Solapure S; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Patil V; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Henrich PP; Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York 10032, USA., Magistrado PA; Harvard School of Public Health, 665 Huntington Avenue, Boston, Massachusetts 02115, USA., Bharath S; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Murugan K; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Viswanath P; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Puttur J; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Srivastava A; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Bellale E; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Panduga V; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Shanbag G; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Awasthy D; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Landge S; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Morayya S; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Koushik K; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Saralaya R; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Raichurkar A; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Rautela N; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Roy Choudhury N; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Ambady A; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Nandishaiah R; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Reddy J; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Prabhakar KR; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Menasinakai S; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Rudrapatna S; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Chatterji M; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Jiménez-Díaz MB; Tres Cantos Medicines Development Campus. Diseases of Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain., Martínez MS; Tres Cantos Medicines Development Campus. Diseases of Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain., Sanz LM; Tres Cantos Medicines Development Campus. Diseases of Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain., Coburn-Flynn O; Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York 10032, USA., Fidock DA; Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York 10032, USA.; Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, New York 10032, USA., Lukens AK; Harvard School of Public Health, 665 Huntington Avenue, Boston, Massachusetts 02115, USA., Wirth DF; Harvard School of Public Health, 665 Huntington Avenue, Boston, Massachusetts 02115, USA., Bandodkar B; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Mukherjee K; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., McLaughlin RE; AstraZeneca Infection Innovative Medicines, 35 Gatehouse Drive, Waltham, Massachusetts 02451, USA., Waterson D; Medicines for Malaria Venture, International Center Cointrin, Geneva 1215, Switzerland., Rosenbrier-Ribeiro L; AstraZeneca, Alderley Park, Cheshire SK10 4TF, UK., Hickling K; AstraZeneca, Alderley Park, Cheshire SK10 4TF, UK., Balasubramanian V; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Warner P; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Hosagrahara V; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Dudley A; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Iyer PS; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Narayanan S; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India., Kavanagh S; AstraZeneca, Alderley Park, Cheshire SK10 4TF, UK., Sambandamurthy VK; Department of Innovative Medicines, AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India.
Publikováno v: Nature communications [Nat Commun] 2015 Mar 31; Vol. 6, pp. 6715. Date of Electronic Publication: 2015 Mar 31.
Zobrazit plný text záznamu
5
Akademický článek
Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
Autor: Hameed P S; Department of Medicinal Chemistry; ‡Department of Biosciences and §DMPK and Animal Sciences, AstraZeneca India Pvt. Ltd. , Bellary Road, Hebbal, Bangalore 560024, India., Patil V, Solapure S, Sharma U, Madhavapeddi P, Raichurkar A, Chinnapattu M, Manjrekar P, Shanbhag G, Puttur J, Shinde V, Menasinakai S, Rudrapatana S, Achar V, Awasthy D, Nandishaiah R, Humnabadkar V, Ghosh A, Narayan C, Ramya VK, Kaur P, Sharma S, Werngren J, Hoffner S, Panduga V, Kumar CN, Reddy J, Kumar K N M, Ganguly S, Bharath S, Bheemarao U, Mukherjee K, Arora U, Gaonkar S, Coulson M, Waterson D, Sambandamurthy VK, de Sousa SM
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2014 Jun 12; Vol. 57 (11), pp. 4889-905. Date of Electronic Publication: 2014 May 23.
Zobrazit plný text záznamu
6
Akademický článek
Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis.
Autor: P SH; AstraZeneca India Pvt Ltd., Hebbal, Bangalore, India., Solapure S, Mukherjee K, Nandi V, Waterson D, Shandil R, Balganesh M, Sambandamurthy VK, Raichurkar AK, Deshpande A, Ghosh A, Awasthy D, Shanbhag G, Sheikh G, McMiken H, Puttur J, Reddy J, Werngren J, Read J, Kumar M, R M, Chinnapattu M, Madhavapeddi P, Manjrekar P, Basu R, Gaonkar S, Sharma S, Hoffner S, Humnabadkar V, Subbulakshmi V, Panduga V
Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2014; Vol. 58 (1), pp. 61-70. Date of Electronic Publication: 2013 Oct 14.
Zobrazit plný text záznamu
7
Akademický článek
Synthesis and Cytotoxic Activity of Novel Chalcone Analogues with Pyridine-2,4(1Н,3Н)-dione Fragment.
Autor: Khlebniсova, T. S.1 khlebnicova@iboch.by, Rubinov, D. B.1, Baranovsky, A. V.1, Lakhvich, F. A.1, Pashkovsky, F. S.1, Chukarina, T. V.1, Ogurtsova, S. E.1
Publikováno v: Russian Journal of General Chemistry. Mar2023, Vol. 93 Issue 3, p476-484. 9p.
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Akademický článek
Synthesis and DABCO‐induced demethylation of 3‐cyano‐4‐methoxy‐2‐pyridone derivatives.
Autor: Li, Jing1 (AUTHOR), Tan, Hong‐Ru1 (AUTHOR), An, Yu‐Long1 (AUTHOR), Shao, Zhi‐Yu1 (AUTHOR), Zhao, Sheng‐Yin1 (AUTHOR) syzhao8@dhu.edu.cn
Publikováno v: Journal of Heterocyclic Chemistry. Jan2020, Vol. 57 Issue 1, p486-496. 11p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje